🇺🇸 FDA
Company

CRISPR

CRISPR Therapeutics AG

CRSP biotech USA

Quick answer

CRISPR is a biotech company (CRSP) headquartered in ZUG, USA with 14 tracked pipeline programs.

Pipeline (14)

project

CTX001

Beta-Thalassemia

Phase 3 · mab · active

3 trials project

CTX001

Sickle Cell Disease

Phase 3 · mab · active

2 trials project

CTX110

B-cell Malignancy

Phase 2 · mab · terminated

1 trials project

CTX112

Warm Autoimmune Hemolytic Anemia (WAIHA)

Phase 2 · mab · active

1 trials project

CTX112

B-cell Lymphoma

Phase 2 · mab · active

1 trials project

CTX131

Clear Cell Renal Cell Carcinoma

Phase 2 · mab · completed

1 trials project

CTX131

T Cell Lymphoma

Phase 2 · mab · completed

1 trials project

CTX112

SLE (Systemic Lupus)

Phase 1 · mab · active

1 trials project

CTX120

Multiple Myeloma

Phase 1 · mab · terminated

1 trials project

CTX130

Renal Cell Carcinoma

Phase 1 · mab · terminated

1 trials project

CTX130

T Cell Lymphoma

Phase 1 · mab · terminated

1 trials project

CTX310

Cardiovascular

Phase 1 · small_molecule · active

1 trials project

VCTX210A unit

Diabetes Mellitus

Phase 1 · other · completed

1 trials project

VCTX211

Diabetes Mellitus

Phase 1 · other · terminated

1 trials

Patents (8)

patent

US 12427170

Universal donor cells

Expires Mon Sep 25 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12344655

Gene-edited natural killer cells

Expires Mon Jun 26 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12344656

Genetically engineered T cells having improved persistence in culture

Expires Mon Jun 26 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12304968

T-cells expressing anti-LIV1 chimeric antigen receptor

Expires Mon May 15 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12263227

Optimized mRNA encoding CAS9 for use in LNPs

Expires Mon Mar 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12247201

Materials and methods for treatment of autosomal dominant retinitis pigmentosa

Expires Mon Mar 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12241087

Compositions and methods for differentiating stem cells into NK cells

Expires Mon Feb 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12227763

Methods and compositions for treating cancer

Expires Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)